Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Oncology

Chronic Myeloid Leukemia

Arizona

Peoria : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Phoenix : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

California

Duarte : City of Hope

A Phase I Dose Escalation Study of LBH589 in Combination with Imatinib Mesylate for Patients with Chronic Myeloid Leukemia in Cytogenetic Remission with Residual Disease Detectable by Q-PCR

Duarte : City of Hope

A Phase II Multicenter Trial of Myeloablative Double Unit Umbilical Cord Blood Transplantation (UCBT) in Adults with Hematologic Malignancy

Duarte : City of Hope

An International Collaboration to Study Interphase Nuclei with FISH to Detect Clinically Significant Chromosome Abnormalities in Peripheral Blood (PB) and Bone Marrow (BM) in Myelodysplastic Syndromes (MDS)

Duarte : City of Hope

Immune Studies in Chronic Myelogenous Leukemia (CML)

Duarte : City of Hope

SWOG 9007: Cytogenetic Studies In Leukemia Patients

Los Angeles : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Los Angeles : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Santa Rosa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Colorado

Denver : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Connecticut

New Britain : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Delaware

Wilmington : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Florida

Hialeah : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Georgia

Atlanta : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Illinois

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Chicago : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Hines : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Indiana

Beech Grove : Indiana Blood and Marrow Transplantation, LLC

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Louisiana

New Orleans : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Maryland

Baltimore : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Massachusetts

Boston : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Missouri

Saint Louis : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New Jersey

Newark : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York

Bronx : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Buffalo : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

East Syracuse : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

New York : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Rochester : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Stony Brook : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Rhode Island

Providence : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Tennessee

Memphis : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Texas

Houston : Research Center

A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (HHT) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation (Protocol CGX-635-CML-202)

Houston : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Washington

Seattle : Merck

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Australia

South Granville : Merck Sharp & Dohme (Australia) Pty Ltd.

Clinical trial of an investigational vaccine for the prevention of shingles and shingles-related complications in immunocompromised individuals

Austria

Graz : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Wien : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Bulgaria

Pleven : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Sofia : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Sofia : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Varna : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Canada

Halifax, NS : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Halifax, NS : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

London, ON : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Ottawa, ON : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Toronto, ON : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

China

Hong Kong : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Czech Republic

Olomouc : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Praha : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

France

Lille : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Lyon : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Paris : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Poitiers : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Strasbourg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Germany

Freiburg : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Hannover : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Mainz : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Mainz : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Mannheim : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Mannheim : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Marburg : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Tübingen : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Tübingen : Research Site:

Expanded Access Program - A Study Providing Long-Term Treatment with PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Myelogenous Leukemia

Hungary

Budapest : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

India

Ahmedabad : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Hyderabad : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Lucknow : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Lucknow : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Trivandrum : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Israel

Haifa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Rehovot : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Italy

Bari : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Bologna : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Pavia : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Pisa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Roma : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Torrette di Ancona : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Udine : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Mexico

Monterrey : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Poland

Warszawa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Russian Federation

Moscow : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Moscow : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

St Petersburg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Slovakia

Banska Bystrica : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Bratislava : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Kosice : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Kosice : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

South Africa

Cape Town : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Durban : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Durban : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Johannesburg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Spain

Barcelona : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Madrid : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Toledo : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Valencia : Research Site:

A Study to Provide Patients Who Have Responded to Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) or Roferon-A (Interferon alfa-2a, Recombinant) in Prior Clinical Studies Continued Access to the Drug

Zaragoza : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Taiwan

Taipei : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

Thailand

Bangkok : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

United Kingdom

Glasgow : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia

London : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) versus Roferon-A (Interferon alfa-2a, Recombinant) in Patients With Recently Diagnosed Chronic Myelogenous Leukemia